[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE04813B1 - Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks - Google Patents

Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks

Info

Publication number
EE04813B1
EE04813B1 EEP200100619A EEP200100619A EE04813B1 EE 04813 B1 EE04813 B1 EE 04813B1 EE P200100619 A EEP200100619 A EE P200100619A EE P200100619 A EEP200100619 A EE P200100619A EE 04813 B1 EE04813 B1 EE 04813B1
Authority
EE
Estonia
Prior art keywords
preparation
prophylaxis
drug
treatment
diseases due
Prior art date
Application number
EEP200100619A
Other languages
English (en)
Inventor
Ritzeler Olaf
Ulrich Stilz Hans
Neises Bernhard
Jerome Bock William Jr.
Walser Armin
A. Flynn Gary
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999128424 external-priority patent/DE19928424A1/de
Priority claimed from DE2000106297 external-priority patent/DE10006297A1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200100619A publication Critical patent/EE200100619A/et
Publication of EE04813B1 publication Critical patent/EE04813B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EEP200100619A 1999-06-23 2000-06-09 Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks EE04813B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999128424 DE19928424A1 (de) 1999-06-23 1999-06-23 Substituierte Benzimidazole
DE2000106297 DE10006297A1 (de) 2000-02-12 2000-02-12 Substituierte Benzimidazole
PCT/EP2000/005340 WO2001000610A1 (de) 1999-06-23 2000-06-09 Substituierte benzimidazole

Publications (2)

Publication Number Publication Date
EE200100619A EE200100619A (et) 2003-02-17
EE04813B1 true EE04813B1 (et) 2007-04-16

Family

ID=26004312

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100619A EE04813B1 (et) 1999-06-23 2000-06-09 Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks

Country Status (29)

Country Link
US (1) US6358978B1 (et)
EP (1) EP1194425B1 (et)
JP (1) JP4763949B2 (et)
KR (1) KR100718830B1 (et)
CN (1) CN1168727C (et)
AT (1) ATE301651T1 (et)
AU (1) AU769350B2 (et)
BR (1) BR0012450B1 (et)
CA (1) CA2377085C (et)
CZ (1) CZ302775B6 (et)
DE (1) DE50010931D1 (et)
DK (1) DK1194425T3 (et)
EE (1) EE04813B1 (et)
ES (1) ES2246240T3 (et)
HK (1) HK1047582B (et)
HR (1) HRP20010944B1 (et)
HU (1) HU228466B1 (et)
IL (1) IL147184A0 (et)
ME (1) MEP56108A (et)
MX (1) MXPA01012283A (et)
NO (1) NO323597B1 (et)
NZ (1) NZ516348A (et)
PL (1) PL206826B1 (et)
PT (1) PT1194425E (et)
RS (1) RS50340B (et)
RU (1) RU2261248C2 (et)
SI (1) SI1194425T1 (et)
SK (1) SK286857B6 (et)
WO (1) WO2001000610A1 (et)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098312B2 (en) * 1998-09-01 2006-08-29 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
MXPA03003599A (es) 2000-10-26 2003-08-01 Tularik Inc Agentes antiinflamatorios.
DE10115073A1 (de) * 2001-03-27 2002-10-10 Procorde Gmbh Verwendung von Inhibitoren von IKK-ß und Verfahren zum Auffinden solcher Inhibitoren
GEP20053660B (en) * 2001-03-28 2005-11-10 Bristol Myers Squibb Co Novel Tyrosine Kinase Inhibitors
US7405235B2 (en) * 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002367953C1 (en) * 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
WO2002101101A2 (en) * 2001-06-13 2002-12-19 Billiton Sa Limited Solvent extraction mixture comprising substituted imidazole or benzimidazole for the purification of base metals
WO2002101182A2 (en) * 2001-06-13 2002-12-19 Billiton Sa Limited Solvent extraction mixture comprising substituted imidazole or benzimidazole for the separation of groups of base metals
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
EP1474425B9 (en) 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
CN1939529A (zh) 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
EP1470626A1 (de) 2002-01-30 2004-10-27 Siemens Aktiengesellschaft Einrichtung zum kurzschliessen von zwei elektrischen leitungen zum abbau einer potentialdifferenz
ES2437391T3 (es) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Compuestos de heteroarilo útiles como inhibidores de GSK-3
US20080114015A1 (en) * 2002-05-31 2008-05-15 Board Of Trustees Of Michigan State University NF-kB inhibitors and uses thereof
US7528161B2 (en) * 2002-05-31 2009-05-05 Michigan State University NF-kappaB inhibitors and uses thereof
MXPA04011246A (es) 2002-06-06 2005-06-03 Boehringer Ingelheim Pharma Compuestos de amidas de acido 3-amino-tieno[2,3-b]piridin-2-carboxilico sustituido y procesos para preparar y sus usos.
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
JP4483581B2 (ja) * 2002-08-06 2010-06-16 東レ株式会社 腎疾患治療又は予防剤及び腎疾患の診断方法
EP1546089A2 (en) * 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) * 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
RS20050195A (en) * 2002-09-17 2007-08-03 Warner Lambert Company Llc., Heterocyclic substituted piperazines for the treatment of schizophrenia
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
JP2006513159A (ja) * 2002-11-01 2006-04-20 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
US7640843B2 (en) 2003-01-24 2010-01-05 Kraft Foods R & D, Inc. Cartridge and method for the preparation of beverages
US20050256132A1 (en) * 2003-04-30 2005-11-17 Wyeth Use of ER selective NF-kB inhibitors for the treatment of sepsis
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US20050147608A1 (en) * 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
ES2345257T3 (es) * 2003-09-08 2010-09-20 Aventis Pharmaceuticals Inc. Tienopirazoles.
JP2007527412A (ja) * 2003-10-24 2007-09-27 エグゼリクシス， インコーポレイテッド Ｔａｏキナーゼモジュレーターおよび使用方法
CA2548011A1 (en) * 2003-12-05 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
NZ555982A (en) 2004-12-30 2011-01-28 Astex Therapeutics Ltd Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
EP1836199A1 (en) * 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
ZA200707896B (en) * 2005-03-14 2009-07-29 High Point Pharma Llc Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
CA2602624A1 (en) * 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as angiotensin ii antagonist
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
EP1896014A4 (en) 2005-06-30 2010-07-21 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2007084728A2 (en) * 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
PE20080130A1 (es) 2006-03-31 2008-02-25 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
US7589087B2 (en) 2006-03-31 2009-09-15 Janssen Pharmaceutica, N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor
JP2009539865A (ja) 2006-06-06 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
EP2038274A2 (en) * 2006-06-23 2009-03-25 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US8435970B2 (en) * 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
EP2043635A2 (en) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
WO2008030584A2 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US20090131481A1 (en) * 2007-03-27 2009-05-21 Paratek Pharmaceuticals, Inc. Transcription Factor Modulating Compounds and Methods of Use Thereof
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2711957C (en) 2007-10-11 2019-03-19 The Regents Of The University Of California Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2009134847A1 (en) * 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
JP5758292B2 (ja) * 2008-07-03 2015-08-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8343997B2 (en) 2008-12-19 2013-01-01 Sirtris Pharmaceuticals, Inc. Thiazolopyridine sirtuin modulating compounds
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
US20110059962A1 (en) * 2009-04-22 2011-03-10 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
CA2770116C (en) 2009-08-10 2018-03-13 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CA2770320A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011045415A2 (en) * 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP5822844B2 (ja) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびその治療的使用
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX339243B (es) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US9856534B2 (en) 2011-04-29 2018-01-02 Emory University Selecting use of proteasome inhibitors based on NF-κB2 sequence
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20141678A1 (es) 2011-09-14 2014-11-21 Samumed Llc Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013078430A1 (en) * 2011-11-22 2013-05-30 The Regents Of The University Of California Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa)
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
RU2689141C2 (ru) 2012-05-04 2019-05-24 СЭМЬЮМЕД, ЭлЭлСи 1н-пиразоло[3,4-b]пиридины и их терапевтические применения
MX370487B (es) 2013-01-08 2019-12-16 Samumed Llc Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
UY35370A (es) 2013-03-06 2014-09-30 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4
WO2014144547A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
WO2014144836A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors
WO2015100225A1 (en) 2013-12-27 2015-07-02 Novus International Inc. Ethoxylated surfactants
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
CA3004297A1 (en) 2015-11-06 2017-05-11 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
PL3464285T3 (pl) 2016-06-01 2023-02-06 Biosplice Therapeutics, Inc. Sposób wytwarzania n-(5-(3-(7-(3-fluorofenylo)-3h-imidazo[4,5-c]pirydyn-2-ylo)-1h-indazol-5-ilo)pirydyn-3-ylo)-3-metylobutanoamidu
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
JP7278945B2 (ja) * 2016-09-20 2023-05-22 サントル レオン ベラール 抗癌剤としてのベンゾイミダゾール誘導体
PE20191153A1 (es) 2016-09-28 2019-09-05 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos
CA3041291A1 (en) 2016-10-21 2018-04-26 Samumed, Llc Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
JP2019533702A (ja) 2016-11-07 2019-11-21 サミュメッド リミテッド ライアビリティ カンパニー 単回用量の調整済み注射用製剤
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
US11447482B1 (en) 2019-02-14 2022-09-20 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH632628B (de) * 1976-07-26 Ciba Geigy Ag Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller.
DE2641060A1 (de) * 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4264325A (en) * 1977-02-22 1981-04-28 Ciba-Geigy Corporation Phenyl-benzimidazolyl-furanes for optical brightening of organic materials
LU85544A1 (fr) * 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
US4804658A (en) * 1986-09-15 1989-02-14 G. D. Searle & Co. Imidazopyridine derivatives and pharmaceutical compositions
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
CA2168016C (en) * 1994-05-31 2000-09-26 Akio Matsunaga Benzimidazole derivatives
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
JP2002517396A (ja) * 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物

Also Published As

Publication number Publication date
NO20016154L (no) 2002-02-19
HK1047582B (zh) 2005-03-04
SK286857B6 (sk) 2009-06-05
HRP20010944A2 (en) 2003-10-31
DK1194425T3 (da) 2005-11-21
PL206826B1 (pl) 2010-09-30
SK18762001A3 (sk) 2002-06-04
YU90801A (sh) 2004-09-03
EP1194425B1 (de) 2005-08-10
WO2001000610A1 (de) 2001-01-04
NO323597B1 (no) 2007-06-11
CA2377085A1 (en) 2001-01-04
KR20020012291A (ko) 2002-02-15
CA2377085C (en) 2011-02-15
ES2246240T3 (es) 2006-02-16
NO20016154D0 (no) 2001-12-17
HRP20010944B1 (en) 2010-08-31
IL147184A0 (en) 2002-08-14
BR0012450B1 (pt) 2011-08-23
EP1194425A1 (de) 2002-04-10
EE200100619A (et) 2003-02-17
RS50340B (sr) 2009-11-10
HUP0202028A2 (en) 2002-10-28
CZ20014526A3 (cs) 2002-03-13
SI1194425T1 (sl) 2005-12-31
CN1356995A (zh) 2002-07-03
KR100718830B1 (ko) 2007-05-17
BR0012450A (pt) 2002-04-02
NZ516348A (en) 2003-06-30
JP2003503400A (ja) 2003-01-28
JP4763949B2 (ja) 2011-08-31
MXPA01012283A (es) 2002-07-30
ME00370B (me) 2011-05-10
DE50010931D1 (de) 2005-09-15
HK1047582A1 (en) 2003-02-28
CZ302775B6 (cs) 2011-11-02
HU228466B1 (en) 2013-03-28
MEP56108A (en) 2011-05-10
AU5404200A (en) 2001-01-31
PL352399A1 (en) 2003-08-25
ATE301651T1 (de) 2005-08-15
RU2261248C2 (ru) 2005-09-27
PT1194425E (pt) 2005-10-31
AU769350B2 (en) 2004-01-22
CN1168727C (zh) 2004-09-29
US6358978B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
EE04813B1 (et) Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks
EE05036B1 (et) Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
PT1147110E (pt) Derivados de pirazino (aza)-indol
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
NO20023362L (no) 1,2-diarylbenzimidazoler for behandling av sykdommer assosiert med en mikrogliaaktivering
SE9802208D0 (sv) Novel compounds
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
SE9802209D0 (sv) Novel compounds
NO982863L (no) Nye forbindelser med analgetisk effekt
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
BR0312424A8 (pt) derivados de pirazoloisoquinolinas para inibição de quinase indutora de nfkappab
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
UA85389C2 (ru) Применение циклических биоизостеров производных пуриновой системы для лечения расстройств, вызванных нарушениями нитрэргической и дофаминергической систем
CO5200841A1 (es) Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos
SE9802207D0 (sv) Novel compounds

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20180609